ORYX GMBH & CO. KG
ORYX’ development strategy bridges the gap between academic research and the pharmaceutical industry for new cancer therapies. Today, the company is developing three clinical cancer immunotherapy projects in indications with high unmet medical need. ORYX is the exclusive licensee of premier cancer immunotherapy substances from the German Cancer Research Center (DKFZ) and the University of Heidelberg. The Company has established close collaborations with DKFZ, Heidelberg University Hospital, National Center for Tumor Diseases (NCT), Nordwest Hospital Frankfurt, Darmstadt Clinic and leading experts as well as an outstanding network of scientific and clinical advisors.
ORYX GMBH & CO. KG
Social Links:
Industry:
Biotechnology Health Care Pharmaceutical
Founded:
2007-01-01
Address:
Baldham, Bayern, Germany
Country:
Germany
Website Url:
http://www.oryx-medicine.com
Status:
Active
Contact:
+49-8106-21 311-0
Email Addresses:
[email protected]
Technology used in webpage:
Google Maps GStatic Google Static Content Google Maps API 3 To 9 CcTLD Redirects
Similar Organizations
Current Employees Featured
Founder
Official Site Inspections
http://www.oryx-medicine.com Semrush global rank: 5.89 M Semrush visits lastest month: 1.4 K
- Host name: aacb0a264e514dd48.awsglobalaccelerator.com
- IP address: 99.83.190.102
- Location: Seattle United States
- Latitude: 47.54
- Longitude: -122.3032
- Metro Code: 819
- Timezone: America/Los_Angeles
- Postal: 98108
More informations about "Oryx GmbH & Co. KG"
ABOUT - ORYX Medicine
We are a German clinical-stage biotech company based near Munich and world-wide connected. Our focus lies on fighting cancer as one of the most devastating civilization disease of the 21st …See details»
ORYX Medicine
We are a German biotech company with a distinctive strategy to fight cancer. Our clout relies on each of our individuals' and partners' experience that is combined in teamwork.See details»
ORYX Pipeline - ORYX Medicine
Scientific Base. H-1 parvovirus. Drug Class. Oncolytic cancer virotherapy. Indication. Certain solid cancers. Development Status. Phase 2a completedSee details»
Oryx GmbH & Co. KG - Crunchbase Company Profile
ORYX’ development strategy bridges the gap between academic research and the pharmaceutical industry for new cancer therapies. Today, the company is …See details»
ORYX GmbH & Co. KG - VentureRadar
Website: https://www.oryx-medicine.com. Develops promising cancer projects from research institutions, overseeing a portfolio of 3 projects in phase I/IIa clinical development with …See details»
Orphanet: ORYX GmbH & Co. KG
ORYX GmbH & Co. KG. Marktplatz 1. 85598 BALDHAM . GERMANY. Phone 1: 00 49 (0)8106 21 311 0 Contact email: [email protected]. Institution's website EUGT Number: 489382 …See details»
Oryx Translational Medicine - 2025 Company Profile - Tracxn
Feb 21, 2025 ORYX Reports Positive Clinical Evidence With Oncolytic Virus ParvOryx In Combination With Immuno Oncology DrugsBioSpace • May 23, 2017 • Oryx Translational …See details»
ORYX Translational Medicine Overview - SignalHire
ORYX Translational Medicine is a private company. The company currently specializes in the Biotechnology area. The ORYX Translational Medicine annual revenue is estimated at < 1M ...See details»
ORYX Company Profile - Office Locations, Competitors, Revenue
ORYX has 5 employees at their 1 location. See insights on ORYX including office locations, competitors, revenue, financials, executives, subsidiaries and more at Craft. ... ORYX …See details»
ORYX GmbH & Co. KG - Drug pipelines, Patents, Clinical trials
Last update 07 Mar 2025. ORYX GmbH & Co. KG. Private Company |See details»
Oryx Translational Medicine - Drug pipelines, Patents, Clinical trials ...
Last update 23 Jan 2025. Oryx Translational Medicine. 2007 |See details»
Oryx Translational Medicine - PitchBook
Oryx Translational Medicine was founded in 2007. Where is Oryx Translational Medicine headquartered? Oryx Translational Medicine is headquartered in Baldham, Germany. What …See details»
German Biotech Tops Up its Oncolytic Virus with Immuno …
May 23, 2017 Based in Munich, Oryx is developing cancer immunotherapies for a number of solid tumors consisting of oncolytic viruses and peptide vaccines. The company just …See details»
About Oryx | Oryx Medical Inc.
Oryx Medical is committed to excellence by carefully selecting device manufacturers who are aligned in delivering the highest quality product with a commitment to superior customer …See details»
Colorectal cancer vaccine - Oryx GmbH & Co. - AdisInsight
If your organization has a subscription, there are several access options, even while working remotely: Working within your organization’s network Login with username/password or try to …See details»
ORYX News - oryx-medicine.com
ORYX to attend CIMT 2024 June 26, 2023. New Website launched. May 28, 2023. Prof. Dr. zur Hausen passed away. May 21, 2023. Article about ParvOryx published online in peer …See details»
ORYX Provides Strategic Update on the Clinical Development
Munich (Germany), November 4, 2019: ORYX, a translational medicine company focused on oncolytic virotherapy and cancer vaccines, today provided an update on the development …See details»
ORYX® for Hospitals Fact Sheet | The Joint Commission
(National Hospital Quality Measures) The Joint Commission’s ORYX ® initiative integrates performance measurement data into the accreditation process. ORYX ® measurement …See details»
ORYX GmbH & Co. KG (ORYX GmbH & Co. KG) - 药物管线_专利_ …
项与 ORYX GmbH & Co. KG 相关的文献（医药） 2021-10-15 · Clinical cancer research : an official journal of the American Association for Cancer Research 1区 · 医学 Phase 2 Trial of …See details»
Reviewing the data: What ORYX means to you - Relias Media
Oct 1, 1998 Nowhere is the need for access to outcomes data more important than with regard to the ORYX initiative put forth by the Joint Commission on Accreditation of Healthcare …See details»